drugset / Trial / NCT04442490

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

NCT04442490

Phase 3 Completed 543 enrolled Biogen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.

Timeline

Start
2020-05-12
Primary completion
2021-03-26
Completion
2021-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Zuranolone Small molecule 40 mg Oral
Subject Zuranolone Small molecule 50 mg Oral